Newly identified events in the RE-LY trial.

By S. Connolly, M. Ezekowitz, S. Yusuf, P. Reilly, L. Wallentin. New England Journal of Medicine, 2010

733 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/2143519647d6911fdff4135caba0a87fc7880fb7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Ezekowitz
2. J. Halperin
3. M. Mack
4. Judith Hochman
5. Gerhard Hindricks
6. M. Creager
7. C. Yancy

In Internal Medicine

1. J. Halperin

Citations in the corpus

• 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011, background): “…Population/Inclusion and Exclusion Criteria Endpoint(s) Statistical Analysis Reported CI and/or p Values OR/HR/RR/Other Study Conclusion ACTIVE A, Connolly et al. (10) To investigate whether the addition of clopidogrel to ASA would reduce risk of vascular events in patients with AF considered…”
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, background): “0 (Table 4).(70,71) For the primary efficacy endpoint of stroke and systemic embolism, D150 was superior to warfarin, with no significant difference in the primary safety endpoint of major bleeding.”
• Dabigatran versus warfarin in patients with mechanical heart valves. (2013, background): “Previous myocardial infarction 9 (5) 7 (8)”
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “associated with less stroke or systemic embolism.(425,426) The”
• The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014, methodology): “Compared with DE 110, exposure to dabigatran was increased by 36% with DE 150 (4), resulting in a 39% reduction in strokes/ systemic emboli but at the cost of a 16% increase in major bleeding (1,2).”